Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 14/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 12/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 11/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608055 | 0.91 | IDO1 (0.45) | PRKCQMCHR1ADRA2ANPY5REPHX2 | |
| SCHEMBL3844891 | 0.88 | PRKCQ (0.54) | PRKCQCYP2C9 | |
| SCHEMBL3852089 | 0.86 | PRKCQ (0.42) | PRKCQCYP2C9 | |
| SCHEMBL13608057 | 0.80 | PRKCQ (0.51) | PRKCQCYP2C9 | |
| SCHEMBL3846914 | 0.79 | MCHR1 (0.42) | MCHR1ADRA2ANPY5REPHX2 | |
| SCHEMBL13608044 | 0.79 | IDO1 (0.48) | PRKCQ | |
| SCHEMBL3843907 | 0.75 | PRKCQ (0.56) | PRKCQCYP2C9 | |
| SCHEMBL3849434 | 0.75 | EPHX2 (0.44) | PRKCQEPHX2HDAC3HDAC1HDAC2 | |
| SCHEMBL3845823 | 0.75 | PRKCQ (0.41) | PRKCQ | |
| SCHEMBL3847762 | 0.74 | GRIN2B (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | PRKCQ 3/4885MCHR1 3804/4885ADRA2A 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.